US Inflation Expected to Rise Again in April as Fed Signals Higher Interest Rates 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Norway Core Inflation Hits 3.2% in April, Fueling Interest Rate Hike Expectations 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Oil Prices Rise as Dollar Gains Ahead of Key U.S. Inflation Data 
Trump Says Iran Ceasefire ‘On Life Support’ as Oil Prices Surge Above $104 
Arcadia Mayor Eileen Wang Pleads Guilty in China Foreign Agent Case 
Argentina Court Upholds Cristina Kirchner Asset Seizure in Corruption Case 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Bolsonaro Discharged After Shoulder Surgery Amid Ongoing Legal Troubles 
U.S. Army Soldier Charged in $400K Insider Betting Scheme on Maduro Capture 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Gold Prices Hold Firm as Traders Watch U.S.-Iran Ceasefire and Trump-Xi Talks 
Trump-Xi China Summit 2026: Trade Tensions, Taiwan, and Iran Take Center Stage 
KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
